{
  "id": "retinitis-pigmentosa",
  "title": "Retinitis pigmentosa",
  "lang": "en",
  "source_lang": "en",
  "summary": "Retinitis pigmentosa is a genetically diverse group of inherited retinal disorders causing progressive loss of night vision, peripheral vision, and sometimes central vision.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "RP",
    "Rod–cone dystrophy",
    "Pigmentary retinal dystrophy"
  ],
  "generated_at": "2026-11-02",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/retinitis-pigmentosa/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/retinitis-pigmentosa/",
      "json": "https://aiwiki.page/zh/retinitis-pigmentosa.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Retinitis pigmentosa (RP) is a group of inherited disorders in which light-sensitive cells in the retina progressively lose function and die. In the usual form, rod photoreceptors, which support vision in dim light, are affected before cone photoreceptors, which support detailed central vision and color discrimination. The characteristic sequence is difficulty seeing at night, progressive restriction of the visual field, and, in some people, substantial loss of central vision. The name describes pigmentary changes visible inside the eye, but these changes may be absent early in the disease.\n\nRP is not a single condition with a uniform course. It can result from pathogenic variants in many different genes, follow several inheritance patterns, and occur either alone or as part of a disorder involving other organs. Its importance extends beyond reduced visual acuity: loss of peripheral vision and dark adaptation can substantially affect mobility and daily activities even when reading vision remains relatively good. Clinical examination, retinal imaging, electrophysiology, and molecular genetic testing together establish the diagnosis and distinguish its many forms.\n\nThe disorder has become a major model for understanding inherited neurodegeneration and developing retinal treatments. Most forms still lack an established treatment that arrests the underlying degeneration, although associated eye complications can be treated and visual rehabilitation can improve function. Gene replacement is available for a narrowly defined subgroup of inherited retinal disease, while other molecular, cellular, and vision-restoration approaches remain under investigation."
    },
    {
      "heading": "Retinal biology and mechanisms of degeneration",
      "text": "The retina is a layered neural tissue lining the back of the eye. Its outermost sensory cells, the photoreceptors, convert light into electrical signals that pass through retinal circuits to the optic nerve. Rods are highly sensitive and support vision at low illumination; cones function predominantly in brighter conditions and mediate color and fine spatial detail. The central fovea contains a particularly dense concentration of cones, whereas rods predominate across much of the surrounding retina. This arrangement explains why rod dysfunction can cause severe night and peripheral-vision difficulties while central visual acuity remains relatively preserved.\n\nPhotoreceptor outer segments contain specialized membranes in which phototransduction occurs. Absorption of light by visual pigments activates a biochemical cascade that changes cyclic guanosine monophosphate concentrations and closes ion channels. The resulting electrical response alters neurotransmitter release. Photoreceptors continually renew their outer segments, and the adjacent retinal pigment epithelium removes shed material, transports nutrients and waste, and participates in regenerating light-sensitive visual pigments. Disruption of any of these interdependent processes can produce inherited retinal degeneration.\n\nDifferent RP-associated genes affect different parts of this system. Some encode visual pigments or signaling proteins; others govern RNA processing, outer-segment structure, transport through the connecting cilium, or interactions with the retinal pigment epithelium. The connecting cilium is especially important because it links the photoreceptor’s inner segment, where many proteins are produced, to its outer segment. Defective transport can prevent essential components from reaching their destination even when those components themselves are structurally normal.\n\nRod loss often leads to secondary cone degeneration, including in disorders caused by genes expressed principally in rods. Proposed and experimentally supported mechanisms include altered nutrient availability, loss of rod-derived survival signals, oxidative stress, and activation of retinal inflammatory responses. These mechanisms are not mutually exclusive, and their relative importance differs among genetic forms and disease stages. Retinal remodeling also occurs: surviving neurons change their connections and signaling properties after photoreceptor input disappears.\n\nThe characteristic dark “bone-spicule” deposits are produced largely by migration and redistribution of pigment-containing cells into the neural retina. They are a consequence of degeneration rather than its initiating cause. Narrowing of retinal blood vessels and pallor of the optic disc also develop in many cases. Despite the ending “-itis,” RP is not primarily an infectious or inflammatory retinitis. Inflammatory signaling may contribute to progression, but the defining process is inherited retinal degeneration."
    },
    {
      "heading": "Genetic causes and inheritance",
      "text": "RP exhibits extensive genetic heterogeneity: pathogenic variants in many different genes can produce overlapping clinical appearances. Conversely, different variants in one gene may cause distinct disorders, ranging from relatively localized retinal disease to severe early-onset visual impairment. The clinical meaning of a variant depends on its effect on the gene product, the inheritance mechanism, and sometimes additional genetic influences. A gene name alone therefore does not establish an individual’s expected course.\n\nAutosomal dominant RP generally results from a disease-causing variant in one copy of a gene. An affected heterozygous parent has a 50% chance of transmitting that variant in each pregnancy, although penetrance and severity can vary. Important examples include RHO, which encodes rhodopsin, and PRPF31, which encodes a component of the RNA-splicing machinery. Some PRPF31 families show incomplete penetrance: a person may carry a pathogenic variant without developing clinically apparent retinal disease. In dominant disease, a variant may reduce the amount of functional protein or produce a protein that interferes with normal cellular activity.\n\nAutosomal recessive RP usually requires pathogenic variants in both copies of a gene. The variants may be identical or different, provided they affect opposite parental copies. When both parents carry a pathogenic variant in the same recessive disease gene, each pregnancy has a 25% probability of an affected child, a 50% probability of a carrier child, and a 25% probability of a child inheriting neither familial variant. Examples of genes associated with recessive RP include USH2A, EYS, and PDE6B. These probabilities describe each pregnancy independently and do not determine the pattern within a small family.\n\nX-linked RP most commonly involves RPGR or RP2. Males with a pathogenic variant on their single X chromosome are often substantially affected. Heterozygous females can range from having little detectable disease to marked visual impairment, partly because of differences in X-chromosome inactivation across retinal cells. An affected father does not transmit his X chromosome to sons but transmits it to all daughters. A heterozygous mother has a 50% probability of transmitting the variant in each pregnancy.\n\nRare inheritance mechanisms include digenic disease, classically involving particular combinations of PRPH2 and ROM1 variants. Some people have no known affected relatives because of recessive inheritance, a new mutation, a small family, incomplete penetrance, or unrecognized disease in relatives. Such “simplex” cases should not be assumed to be nonhereditary. Genetic counseling interprets inheritance and reproductive implications in the context of a confirmed molecular result and the family pedigree."
    },
    {
      "heading": "Syndromic forms and related retinal disorders",
      "text": "RP may be confined to the eye or form part of a multisystem genetic disorder. This distinction matters because some syndromes involve clinically important abnormalities that are not apparent from the retinal examination. The biological connection often lies in proteins required in several tissues, especially proteins involved in ciliary structure, intracellular transport, or lipid metabolism. Syndromic classification combines the retinal phenotype with hearing, balance, developmental, metabolic, renal, and neurological findings.\n\nUsher syndrome is a major cause of combined inherited retinal degeneration and hearing loss. Its traditional clinical types differ in the severity and timing of hearing impairment, vestibular dysfunction, and retinal disease. Type 1 usually includes congenital severe-to-profound hearing loss and vestibular dysfunction, whereas type 2 generally includes congenital hearing loss with relatively preserved vestibular function. Type 3 is characterized by progressive hearing loss with variable vestibular involvement. Genes such as MYO7A, USH2A, and CLRN1 are associated with these phenotypes, but genotype–phenotype boundaries are not absolute. Some USH2A variants cause retinal disease without clinically significant hearing impairment.\n\nBardet–Biedl syndrome combines retinal dystrophy with variable features that can include postaxial polydactyly, obesity, renal abnormalities, learning difficulties, and reproductive-system abnormalities. Its retinal disease is often described as a cone–rod dystrophy rather than a classic rod–cone dystrophy, illustrating why not every pigmentary retinal degeneration should be treated as identical to nonsyndromic RP. Other ciliopathies can involve retinal degeneration alongside kidney disease, cerebellar abnormalities, or skeletal changes.\n\nAdult Refsum disease is an important metabolic differential because pigmentary retinal degeneration can accompany anosmia, peripheral neuropathy, ataxia, hearing impairment, and other systemic manifestations. The disorder involves impaired phytanic acid metabolism. Abetalipoproteinemia can also cause retinal degeneration together with fat malabsorption and neurological disease. In these conditions, recognizing the systemic diagnosis has implications beyond classification of the eye findings.\n\nSeveral neighboring inherited retinal disorders overlap with RP but differ in their initial cellular targets or age of presentation. Leber congenital amaurosis and early-onset severe retinal dystrophy usually cause major visual dysfunction in infancy or early childhood. Cone–rod dystrophies typically begin with impaired central acuity, color discrimination, or light tolerance before substantial rod dysfunction. Some genes, including RPE65 and CRB1, can produce more than one of these clinical labels. Modern diagnosis therefore uses both the observable phenotype and the molecular cause rather than treating historical disease names as sharply separated biological entities."
    },
    {
      "heading": "Symptoms, examination findings, and ocular complications",
      "text": "The classic early symptom is night blindness, or nyctalopia. Affected people may have difficulty entering a dark room, navigating outdoors after dusk, or recognizing obstacles under low illumination. Dark adaptation can be slow or incomplete. These difficulties may precede obvious pigmentary changes and may not initially be recognized as abnormal, particularly when symptoms begin in childhood. Age at onset varies widely, from early childhood to adulthood, depending partly on the genetic form.\n\nPeripheral visual-field loss commonly begins in the mid-periphery, sometimes as a ring-shaped scotoma. As the affected area expands, remaining vision may become restricted to a central island, often described as tunnel vision. Small peripheral islands can persist in some people. Visual-field restriction can cause collisions with objects or difficulty locating items even when a standard letter chart shows relatively good central acuity. Acuity and visual field therefore measure different aspects of impairment and should not be treated as interchangeable.\n\nCone dysfunction becomes more important as many forms advance. It can cause reduced reading acuity, impaired color discrimination, reduced contrast sensitivity, glare, and difficulty functioning across changes in lighting. Some people experience photopsias, such as flickering or flashing sensations, without an external light source. The usual disease pattern is bilateral and broadly symmetrical, but the severity and distribution of abnormalities can differ between eyes. Marked asymmetry or an apparently unilateral presentation raises additional diagnostic questions.\n\nThe classic fundus appearance comprises mid-peripheral bone-spicule pigmentation, attenuated retinal arterioles, and waxy pallor of the optic disc. These findings are neither all necessary nor individually sufficient for diagnosis. Early disease can have a nearly normal-appearing fundus, and “RP sine pigmento” describes an RP phenotype without the typical pigment deposits. Sector RP affects a limited retinal region, often with a corresponding localized visual-field defect, and may have a different course from generalized disease.\n\nAdditional ocular disorders can contribute to loss of central vision. Posterior subcapsular cataract is relatively common and may produce glare disproportionate to its size. Cystoid macular edema causes fluid-filled spaces in the central retina and can reduce acuity independently of photoreceptor loss. Epiretinal membranes and vitreomacular traction may also occur. Distinguishing these complications from the underlying degeneration is important because some are treatable even when the inherited disease itself cannot yet be halted."
    },
    {
      "heading": "Diagnostic testing and differential diagnosis",
      "text": "Diagnosis rests on the combination of symptoms, family history, retinal examination, functional testing, imaging, and, when informative, molecular genetics. A characteristic appearance alone does not identify the responsible gene. Conversely, a genetic finding must be assessed against the clinical phenotype and inheritance pattern. The diagnostic process also distinguishes progressive retinal degeneration from stationary night-vision disorders and from acquired conditions that resemble RP.\n\nFull-field electroretinography measures the retina’s summed electrical response to standardized flashes under dark-adapted and light-adapted conditions. In typical rod–cone RP, rod-mediated responses are disproportionately reduced early, followed by increasing cone abnormalities. Responses can become undetectable in advanced disease. Because full-field testing reflects broad retinal function, it may not accurately represent a small surviving central island. It is distinct from tests such as pattern electroretinography, which address different aspects of retinal function.\n\nOptical coherence tomography provides cross-sectional images of retinal layers. It can show thinning of the outer nuclear layer, loss or shortening of photoreceptor-associated bands, and preservation of central retinal structure despite peripheral degeneration. The width of the ellipsoid-zone band is frequently used in clinical research as a structural measure of surviving photoreceptors. OCT also detects macular edema, epiretinal membranes, and traction. Fundus autofluorescence maps naturally fluorescent retinal signals; many patients have a hyperautofluorescent ring associated with the transition between better-preserved and more affected retina.\n\nVisual-field testing defines the distribution of functional loss. Kinetic perimetry maps responses to moving targets, while static perimetry tests light sensitivity at fixed locations. Microperimetry relates sensitivity to specific retinal locations while tracking fixation. Tests of dark adaptation, color vision, contrast sensitivity, and full-field stimulus thresholds can provide additional information. No single test captures every clinically meaningful feature, and advanced disease can create floor effects in some measurements.\n\nMolecular testing commonly uses inherited-retinal-disease gene panels, with exome or genome sequencing in selected unresolved cases. Interpretation must consider copy-number changes, difficult-to-sequence regions, deep intronic variants, and whether two recessive variants are on opposite parental copies. A variant of uncertain significance is not equivalent to a confirmed disease-causing variant.\n\nDifferential diagnoses include congenital stationary night blindness, choroideremia, gyrate atrophy, and acquired pigmentary retinopathies. Medication toxicity, including some patterns associated with hydroxychloroquine, autoimmune retinopathy, infections such as syphilis, and previous inflammation or trauma can produce overlapping findings. Exposure history, systemic features, test patterns, and the tempo of visual loss help distinguish these conditions."
    },
    {
      "heading": "Epidemiology and natural history",
      "text": "RP is often estimated to affect approximately one person in 3,000–5,000, with about one in 4,000 commonly cited. These figures describe a heterogeneous group rather than a single molecular disease. Estimates of prevalence vary with population ancestry, case definitions, access to specialist examination, and the extent of genetic testing. Some studies include syndromic forms or related inherited retinal dystrophies, whereas others restrict the category more narrowly.\n\nThe distribution of causal genes and inheritance patterns differs among populations. Founder variants can become relatively frequent in geographically or historically isolated communities. Parental relatedness increases the probability that a child inherits two copies of the same recessive pathogenic variant, but recessive RP also occurs widely without known parental relatedness. Referral-center cohorts may overrepresent severe, early-onset, or genetically distinctive cases and therefore do not necessarily describe the general population.\n\nNatural history is highly variable. Some people develop substantial impairment in childhood, whereas others retain useful central vision into later adulthood. Certain X-linked forms often have an early and severe course, but inheritance pattern alone is not a sufficient prognostic tool. Even relatives with the same causal variant can differ in onset and progression. Modifying genes, variant-specific effects, biological variability, and environmental influences may contribute, although their individual predictive value is often limited.\n\nDifferent outcome measures can also suggest different rates of progression. A person may retain stable letter-chart acuity while losing peripheral sensitivity or retinal structure. Conversely, an episode of macular edema or development of cataract can reduce acuity more rapidly than the underlying degeneration would predict. Longitudinal studies therefore use multiple measurements, including visual fields, OCT, electroretinography, and functional vision assessments.\n\nThe term “blindness” requires careful interpretation in natural-history reports. Legal or administrative definitions may depend on visual-field restriction as well as acuity and do not necessarily mean absence of all light perception. RP does not invariably lead to complete blindness, and a single age at which vision will be lost cannot be assigned to the diagnosis. Molecularly defined cohort studies provide more useful estimates than broad historical averages, particularly when they include repeated measurements over several years. Even these estimates describe groups rather than fixed outcomes for an individual."
    },
    {
      "heading": "Established care, complication treatment, and rehabilitation",
      "text": "Care for RP separates three distinct objectives: treating reversible or manageable ocular complications, preserving function through rehabilitation, and addressing a confirmed molecular cause when an established targeted treatment exists. For most genetic forms, routine care does not include a proven intervention that stops the primary degeneration. Functional improvement from cataract treatment or visual aids should therefore not be confused with reversal of the inherited retinal disease.\n\nCystoid macular edema is commonly treated with carbonic anhydrase inhibitors, administered topically or systemically in selected cases. Anatomical responses vary, and reduction in retinal fluid does not always produce a corresponding gain in acuity. Other treatments, including local corticosteroids, have been studied or used for selected presentations, but their benefits and risks differ. Recurrent edema is possible, and coexisting photoreceptor loss can limit improvement even when the edema resolves.\n\nCataract surgery can improve vision when lens opacity makes a meaningful contribution to visual impairment. The achievable result depends on the condition of the central retina as well as the cataract. RP can be associated with zonular weakness, capsular contraction, and postoperative macular edema, factors relevant to surgical planning and follow-up. Cataract extraction does not restore lost peripheral retina or prevent further inherited degeneration.\n\nVision rehabilitation addresses the mismatch between residual vision and daily tasks. Magnification, electronic reading systems, text-to-speech software, screen readers, and adjustments to contrast and lighting can improve access to information. Orientation and mobility training addresses navigation when peripheral vision or low-light vision is limited. Educational and workplace accommodations may depend more on field loss, contrast sensitivity, and task demands than on distance acuity alone. Assistive technology is therefore relevant across a wide range of disease severity, not only after profound central vision loss.\n\nHistorical studies of vitamin A and other supplements generated substantial debate. Later evidence and reanalyses have not established high-dose vitamin A as a broadly effective treatment across RP genotypes, and supplementation can carry toxicity and reproductive risks. Nutritional interventions cannot be assumed to work uniformly in genetically distinct disorders.\n\nThe effects of RP also extend to quality of life, employment, education, and social participation. When retinal degeneration accompanies hearing impairment, communication access becomes a distinct component of rehabilitation. These functional outcomes are important in their own right and are not adequately represented by retinal imaging or acuity measurements alone."
    },
    {
      "heading": "Gene-directed and other molecular therapies",
      "text": "Gene therapy seeks to modify the biological cause of disease rather than simply compensate for reduced vision. Gene augmentation introduces a functioning gene copy into surviving target cells and is particularly suited to some recessive loss-of-function disorders. It is less straightforward for dominant disease caused by a toxic gene product, where adding a normal copy may not remove the harmful effect. Such disorders may require suppression, editing, replacement, or a combination of approaches.\n\nVoretigene neparvovec is an adeno-associated viral vector treatment carrying a functional RPE65 gene. It was approved in the United States in 2017 and in the European Union in 2018 for specified patients with confirmed biallelic RPE65-associated retinal dystrophy and sufficient viable retinal cells. The treatment is delivered by subretinal injection. RPE65 encodes an enzyme required for regeneration of the visual chromophore, so treatment can improve function in surviving cells whose visual cycle is impaired.\n\nThis approval does not mean that gene therapy is available for RP as a whole. RPE65-associated disease represents a small subset of inherited retinal degeneration and may be classified clinically as early-onset severe retinal dystrophy, Leber congenital amaurosis, or RP. The pivotal trial assessed functional navigation under different light levels using a multi-luminance mobility test. Improvements in light sensitivity and navigation did not imply regeneration of dead photoreceptors, normal vision, or guaranteed prevention of all later degeneration.\n\nInvestigational gene-directed approaches target genes such as RPGR, PDE6B, and others. Technical constraints differ by target. A conventional adeno-associated viral vector has a packaging capacity of approximately 4.7 kilobases, limiting its suitability for large genes. Delivery route determines which retinal cells are reached and introduces different procedural and immune risks. Treatment also requires an appropriate disease stage: genetic correction cannot directly rescue cells that have already disappeared.\n\nAntisense oligonucleotides can alter RNA processing, for example by promoting exclusion of a selected exon or correcting abnormal splicing. Genome-editing strategies aim to change DNA itself, while other approaches seek to reduce toxic gene products or improve common downstream survival pathways. These methods are mutation- or mechanism-dependent and cannot be assumed to benefit all variants in a target gene.\n\nClinical development requires both evidence of biological activity and evidence of meaningful visual benefit. Small patient populations, variable progression, and differences between the two eyes complicate trial design. A treatment’s mechanism, target population, delivery procedure, durability, and safety must therefore be evaluated separately rather than grouped under a general claim that inherited blindness has become curable."
    },
    {
      "heading": "Historical development and current research challenges",
      "text": "The term retinitis pigmentosa is associated with the Dutch ophthalmologist Frans Cornelis Donders in 1857. Its emergence followed the development of the ophthalmoscope, which made it possible to examine the living retina and recognize characteristic pigmentary changes. Early classification was based principally on appearance, symptoms, and family patterns. The name persisted even after the condition was understood to be primarily degenerative rather than inflammatory.\n\nDuring the twentieth century, electroretinography established that widespread retinal dysfunction could be present before the classic fundus appearance became obvious. Molecular genetics then transformed RP from an apparently unified clinical entity into a collection of gene-defined disorders. In 1990, identification of a rhodopsin gene variant associated with autosomal dominant RP provided a landmark connection between a specific molecular defect and the disease. Subsequent discoveries implicated phototransduction, RNA splicing, ciliary transport, and numerous other cellular pathways.\n\nOne research direction seeks mutation-independent protection of surviving cones. Because many genetic forms ultimately converge on cone dysfunction, interventions addressing oxidative stress, metabolic support, or cell-survival signaling could potentially have broader applicability than gene replacement. The principal challenge is demonstrating sustained clinical benefit rather than a short-lived change in a laboratory measure or imaging feature. Mechanistic promise in an animal model does not establish efficacy in human RP.\n\nFor advanced disease, optogenetic strategies aim to make surviving retinal cells responsive to light by introducing light-sensitive proteins. Retinal prostheses instead use electronic stimulation to activate remaining visual pathways. Both approaches differ fundamentally from restoring normal photoreceptor biology, and the visual information they generate is limited by neural remodeling, device or vector performance, and the ability of the nervous system to interpret altered signals. Cell-replacement approaches investigate photoreceptor precursors or retinal tissue derived from stem cells, but functional integration into an extensively remodeled human retina remains a major obstacle.\n\nTrial methodology is another central challenge. Structural measures such as ellipsoid-zone width can be sensitive to change, yet they are not automatically validated surrogate endpoints for how a person sees or functions. Patient-reported outcomes, mobility tasks, low-luminance testing, and retinal sensitivity measurements address different aspects of benefit. A randomized controlled trial must also account for slow progression, small genetically defined populations, learning effects, and limitations of using the fellow eye as a control.\n\nNatural-history datasets and molecularly characterized cohorts help identify suitable endpoints and treatment windows. Their interpretation depends on standardized testing, adequate follow-up, and inclusion of participants across disease stages. The remaining scientific questions include why cones die after rod loss, how much remodeled retina can support restored vision, and which functional changes are sufficiently durable and meaningful to establish treatment benefit."
    }
  ],
  "links": [
    "inflammation",
    "gene",
    "mutation",
    "usher-syndrome",
    "hearing-loss",
    "cataract",
    "diagnosis",
    "optical-coherence-tomography",
    "hydroxychloroquine",
    "syphilis",
    "prevalence",
    "cohort-study",
    "corticosteroid",
    "surgery",
    "rehabilitation",
    "assistive-technology",
    "quality-of-life",
    "gene-therapy",
    "optogenetics",
    "surrogate-endpoint",
    "patient-reported-outcome",
    "randomized-controlled-trial"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}